The effect of fremanezumab was described by a maximum pharmacologic effect of C\text{av}\text{28d} as a fraction of baseline.

**METHODS**

### Phase 2 and 3 Episodic and Chronic Migraine Studies

An exposure–response model was developed to describe the relationship between fremanezumab exposure and response in the number of migraine days in patients with EM. A maximum-effect response model was used to describe the relationship between fremanezumab exposure and response in the number of migraine days in patients with EM. A maximum-effect response model was used to describe the relationship between fremanezumab exposure and response in the number of migraine days in patients with EM.

### Baseline Demographics

**TABLE 1.** Monthly number of migraine days at baseline, stratified by treatment group

<table>
<thead>
<tr>
<th>Baseline characteristic</th>
<th>Fremanezumab</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD)</td>
<td>28.1 (10.3)</td>
<td>27.8 (10.4)</td>
</tr>
<tr>
<td>Min. (Max.)</td>
<td>15 (49)</td>
<td>15 (48)</td>
</tr>
<tr>
<td>n</td>
<td>114 (114)</td>
<td>114 (114)</td>
</tr>
</tbody>
</table>

Results are presented as means (SD), medians (interquartile range [IQR]) or number (%) and stratified by treatment group. Comparisons between treatment groups were made by analysis of variance (ANOVA) for continuous variables and the chi-square test for dichotomous variables with a Bonferroni correction for multiple testing.

**CONCLUSIONS**

Conclusions

- **Higher fremanezumab C\text{av}\text{28d} is predictive of greater reduction in monthly migraine days.**
- **The fremanezumab regimen of 225 mg sc monthly and 675 mg sc quarterly significantly reduced monthly migraine days in a similar fashion during month 1 compared to placebo treatment, an effect which continued during the 3-month treatment.**
- **For the 3-month average response, fremanezumab 225 mg sc monthly and 675 mg sc quarterly regimens achieve similar higher response versus placebo in EM due to the similarity in drug exposure over 3 months for these 2 dose regimens.**

**Figure 5.** Simulated mean (95% confidence interval) monthly number of migraine days and change from baseline in migraine days across monthly and quarterly regimens for all patients with EM. **Figure 6.** Simulated mean and placebo prediction interval of percentage of virtual patients with at least a 50% reduction from baseline in average monthly migraine days at month 3 across 3 treatment groups. **Figure 7.** Simulated mean percentage of virtual patients with at least a 50% reduction from baseline in average monthly migraine days at month 3 across 3 treatment groups.